Recent studies have shown that nanocarriers with 25% PEG installed with glucose for targeting glucose transporter-1 (GLUT-1) in cancer cells can overcome the liver barrier and achieve higher accumulation in tumors and better antitumor activity (57). This evidence concerns the gene SLC2A1 and cancer.